The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy

Gastroenterology

Volumn 156, Issue 7, 2019, Pages 2097-2115.e2

  Sethi, Vrishketan ^a   Vitiello, Gerardo A ^b   Saxena, Deepak ^b,c   Miller, George ^b   Dudeja, Vikas ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

Bacteria; Cancer Immunity; Immunotherapy; Microbiome; Pancreatic Cancer

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ARTICLE; BACTERIAL MICROBIOME; CANCER IMMUNOTHERAPY; CARCINOGENESIS; COLON CANCER; HUMAN; MEDICAL EDUCATION; NONHUMAN; PANCREAS CANCER; PRECLINICAL STUDY; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE; ANIMAL; BACTERIUM; CELL TRANSFORMATION; DRUG EFFECT; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; MICROBIOLOGY; MICROFLORA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; BACTERIA; CELL TRANSFORMATION, NEOPLASTIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MICROBIOTA; PANCREATIC NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85064552194     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.12.045     Document Type: Article

References (217)

1. Is cancer a virus disease?. JAMA 108:5 (1937), 394–395, 10.1001/jama.1937.02780050050016.
2. Perez-Muñoz, M.E., Arrieta, M.-C., Ramer-Tait, A.E., et al. A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the pioneer infant microbiome. Microbiome, 5, 2017, 48.
3. Sender, R., Fuchs, S., Milo, R., Revised estimates for the number of human and bacteria cells in the body. PLoS Biol, 14, 2016, e1002533.
4. Yatsunenko, T., Rey, F.E., Manary, M.J., et al. Human gut microbiome viewed across age and geography. Nature 486 (2012), 222–227.
5. Rothschild, D., Weissbrod, O., Barkan, E., et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555 (2018), 210–215.
6. Vangay, P., Johnson, A.J., Ward, T.L., et al. US immigration Westernizes the human gut microbiome. Cell 175 (2018), 962–972. e10.
7. Waksman, S.A., Woodruff, H.B., The soil as a source of microorganisms antagonistic to disease-producing bacteria. J Bacteriol 40 (1940), 581–600.
8. McCormick, M.H., Mcguire, J.M., Vancomycin and Method for its Preparation. Google Patents, 1962 Available from: https://patents.google.com/patent/US3067099A/en?q=Vancomycin&q=Preparation.
9. Reyniers, J.A., The pure-culture concept and gnotobiotics. Ann NY Acad Sci 78 (1959), 3–16.
10. Reyniers, J.A., Trexler, P.C., Ervin, R.F., Rearing germ-free albino rats. Lobund Rep, 1946, 1–84.
11. Suau, A., Bonnet, R., Sutren, M., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 65 (1999), 4799–4807.
12. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., et al. Diversity, stability and resilience of the human gut microbiota. Nature 489 (2012), 220–230.
13. Taconic Biosciences. Black 6 (B6NTac). Volume 2018;2018.
14. Mallapaty, S., Gnotobiotics: getting a grip on the microbiome boom. Lab Animal, 46, 2017, 373.
15. Saluja, A.K., Dudeja, V., Relevance of animal models of pancreatic cancer and pancreatitis to human disease. Gastroenterology 144 (2013), 1194–1198.
16. The Human Microbiome Project Consortium Methé, B.A., Nelson, K.E., et al. A framework for human microbiome research. Nature, 486, 2012, 215.
17. Peterson, J., Garges, S., Giovanni, M., et al. The NIH Human Microbiome Project. Genome Res 19 (2009), 2317–2323.
18. Hingorani, S.R., Wang, L., Multani, A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
19. Dankort, D., Curley, D.P., Cartlidge, R.A., et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet, 41, 2009, 544.
20. Ijichi, H., Chytil, A., Gorska, A.E., et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev, 20, 2006, 3147v3160.
21. Reikvam, D.H., Erofeev, A., Sandvik, A., et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS One, 6, 2011, e17996.
22. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., et al. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118 (2004), 229–241.
23. Nguyen, T.L.A., Vieira-Silva, S., Liston, A., et al. How informative is the mouse for human gut microbiota research?. Dis Models Mech 8 (2015), 1–16.
24. De Filippo, C., Cavalieri, D., Di Paola, M., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
25. Ericsson, A.C., Davis, J.W., Spollen, W., et al. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PLoS One, 10, 2015, e0116704.
26. Villarino, N.F., LeCleir, G.R., Denny, J.E., et al. Composition of the gut microbiota modulates the severity of malaria. Proc Natl Acad Sci U S A 113 (2016), 2235–2240.
27. Routy, B., Le Chatelier, E., Derosa, L., et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359:6371 (2018 Jan 5), 91–97.
28. Gopalakrishnan, V., Spencer, C.N., Nezi, L., et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359 (2018), 97–103.
29. Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med, 1, 2009 6ra14–6ra14.
30. Beura, L.K., Hamilton, S.E., Bi, K., et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532 (2016), 512–516.
31. Rosshart, S.P., Vassallo, B.G., Angeletti, D., et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171 (2017), 1015–1028.e13.
32. Abolins, S., King, E.C., Lazarou, L., et al. The comparative immunology of wild and laboratory mice, Mus musculus domesticus. Nat Commun, 8, 2017, 14811.
33. Willyard, C., Squeaky clean mice could be ruining research. Nature 556 (2018), 16–18.
34. Ivanov II. Microbe hunting hits home. Cell Host Microbe 21 (2017), 282–285.
35. Ley, R.E., Bäckhed, F., Turnbaugh, P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075.
36. Ridaura, V.K., Faith, J.J., Rey, F.E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341(6150), 2013, 1241214.
37. Wu, H.-J., Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32 (2010), 815–827.
38. Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328 (2010), 228–231.
39. Viaud, S., Saccheri, F., Mignot, G., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976.
40. Dapito, D.H., Mencin, A., Gwak, G.-Y., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer cell 21 (2012), 504–516.
41. Federal RePORTER. Visualization, 2018 Available from: https://federalreporter.nih.gov/Projects/visualize/?searchId=f759f5e7932042e29c97c8a8fd64bbda&searchMode=Smart&resultType=projects.
42. Gaboriau-Routhiau, V., Rakotobe, S., Lecuyer, E., et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31 (2009), 677–689.
43. Thorbecke, G.J., Benacerraf, B., Some histological and functional aspects of lymphoid tissue in germfree animals: II. Studies on phagocytosis in vivo. Ann NY Acad Sci 78 (1959), 247–254.
44. Gordon, H.A., Wostmann, B.S., Morphological studies on the germfree albino rat. Anat Rec 137 (1960), 65–70.
45. Gordon, H.A., The germ-free animal. Am J Digest Dis 5 (1960), 841–867.
46. Round, J.L., Mazmanian, S.K., The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol 9 (2009), 313–323.
47. Schaedler, R.W., Dubos, R., Costello, R., Association of germfree mice with bacteria isolated from normal mice. J Exp Med 122 (1965), 77–82.
48. Dewhirst, F.E., Chien, C.-C., Paster, B.J., et al. Phylogeny of the defined murine microbiota: altered schaedler flora. Appl Environ Microbiol 65 (1999), 3287–3292.
49. Re, F., Strominger, J.L., Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276 (2001), 37692–37699.
50. Abrahams, V.M., Bole-Aldo, P., Kim, Y.M., et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 173 (2004), 4286–4296.
51. Omenetti, S., Pizarro, T.T., The Treg/Th17 Axis: a dynamic balance regulated by the gut microbiome. Front Immunol, 6, 2015, 639.
52. Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122 (2005), 107–118.
53. Mazmanian, S.K., Round, J.L., Kasper, D.L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature, 453, 2008, 620.
54. + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107 (2010), 12204–12209.
55. Atarashi, K., Tanoue, T., Shima, T., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–341.
56. Arpaia, N., Campbell, C., Fan, X., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. Nature 504 (2013), 451–455.
57. Furusawa, Y., Obata, Y., Fukuda, S., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
58. Ivanov II, Frutos, RdL., Manel, N., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4 (2008), 337–349.
59. Ivanov II, Atarashi, K., Manel, N., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139 (2009), 485–498.
60. Gomez De Aguero, M., Ganal-Vonarburg, S.C., Fuhrer, T., et al. The maternal microbiota drives early postnatal innate immune development. Science 351:6279 (2016), 1296–1302.
61. Chow, J., Lee, S.M., Shen, Y., et al. Host-bacterial symbiosis in health and disease. Adv Immunol 107 (2010), 243–274.
62. Zhang, D., Chen, G., Manwani, D., et al. Neutrophil ageing is regulated by the microbiome. Nature 525 (2015), 528–532.
63. Josefsdottir, K.S., Baldridge, M.T., Kadmon, C.S., et al. Antibiotics impair murine hematopoiesis by depleting intestinal microbiota. Blood 129 (2017), 729–739.
64. Mao, K., Baptista, A.P., Tamoutounour, S., et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature 554 (2018), 255–259.
65. Biasucci, G., Benenati, B., Morelli, L., et al. Cesarean delivery may affect the early biodiversity of intestinal bacteria. J Nutr 138 (2008), 1796S–1800S.
66. Mueller, N.T., Bakacs, E., Combellick, J., et al. The infant microbiome development: mom matters. Trends Mol Med 21 (2014), 109–117.
67. Debley, J.S., Smith, J.M., Redding, G.J., et al. Childhood asthma hospitalization risk after cesarean delivery in former term and premature infants. Ann Allergy Asthma Immunol 94 (2005), 228–233.
68. Eggesbo, M., Botten, G., Stigum, H., et al. Is delivery by cesarean section a risk factor for food allergy?. J Allergy Clin Immunol 112 (2003), 420–426.
69. Cardwell, C.R., Stene, L.C., Joner, G., et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 51 (2008), 726–735.
70. Sevelsted, A., Stokholm, J., Bønnelykke, K., et al. Cesarean section and chronic immune disorders. Pediatrics 135 (2015), e92–e98.
71. Dethlefsen L ea, The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol, 6, 2008, e280.
72. Shaw, S.Y., Blanchard, J.F., Bernstein, C.N., Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105 (2010), 2687–2692.
73. Trasande, L., Blustein, J., Liu, M., et al. Infant antibiotic exposures and early-life body mass. Int J Obes (Lond) 37 (2013), 16–23.
74. Cao, Y., Wu, K., Mehta, R., et al. Long-term use of antibiotics and risk of colorectal adenoma. Gut 67 (2018), 672–678.
75. Pannaraj, P.S., Li, F., Cerini, C., et al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. JAMA Pediatr 171 (2017), 647–654.
76. Kull, I., Melen, E., Alm, J., et al. Breast-feeding in relation to asthma, lung function, and sensitization in young schoolchildren. J Allergy Clin Immunol 125 (2010), 1013–1019.
77. Gronlund, M.M., Gueimonde, M., Laitinen, K., et al. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease. Clin Exp Allergy 37 (2007), 1764–1772.
78. Ganguli, K., Meng, D., Rautava, S., et al. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 304 (2013), G132–G141.
79. Plummer, M., de Martel, C., Vignat, J., et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4 (2016), e609–e616.
80. Sobhani, I., Tap, J., Roudot-Thoraval, F., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One, 6, 2011, e16393.
81. Xuan, C., Shamonki, J.M., Chung, A., et al. Microbial dysbiosis is associated with human breast cancer. PLoS One, 9, 2014, e83744.
82. Hanahan, D., Weinberg Robert, A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
83. Rous, P., A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med, 13, 1911, 397.
84. Bittner, J.J., Some possible effects of nursing on the mammary gland tumor incidence in mice. Science (New York, NY), 84, 1936 162–162.
85. Bittner, J.J., The milk-influence of breast tumors in mice. Science 95 (1942), 462–463.
86. Epstein, M.A., Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1 (1964), 702–703.
87. Achong, B.G., Mansell, P.W., Epstein, M.A., et al. An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 46 (1971), 299–307.
88. Mustacchi, P., Shimkin, M.B., Cancer of the bladder and infestation with Schistosoma hematobium. J Natl Cancer Inst 20 (1958), 825–842.
89. Marshall, B.J., Warren, J.R., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984), 1311–1315.
90. Marshall, B.J., Armstrong, J.A., McGechie, D.B., et al. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142 (1985), 436–439.
91. Vakil, N., Megraud, F., Eradication therapy for Helicobacter pylori. Gastroenterology 133 (2007), 985–1001.
92. Zeng, M., Mao, X.-H., Li, J.-X., et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1457–1464.
93. Balakrishnan, M., George, R., Sharma, A., et al. Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep, 19, 2017, 36.
94. Meyerhardt, J.A., Niedzwiecki, D., Hollis, D., et al. Association of dietary patterns with cancer recurrence and survival in patients with stage iii colon cancer. JAMA 298 (2007), 754–764.
95. Giovannucci, E., Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31 (2002), 925–943.
96. Burkitt, D.P., Epidemiology of large bowel disease: the role of fibre. Proc Nutr Soc 32 (1973), 145–149.
97. Filippo, C.D., Cavalieri, D., Paola, M.D., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
98. Serino, M., Luche, E., Gres, S., et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 61 (2012), 543–553.
99. Cummings, J.H., Bingham, S.A., Heaton, K.W., et al. Fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). Gastroenterology 103 (1992), 1783–1789.
100. Lupton, J.R., Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 134 (2004), 479–482.
101. Campbell, J.M., Fahey, G.C. Jr., Wolf, B.W., Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr 127 (2018), 130–136.
102. Wang, T., Cai, G., Qiu, Y., et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6 (2012), 320–329.
103. reg cell homeostasis. Science 341 (2013), 569–573.
104. Singh, N., Gurav, A., Sivaprakasam, S., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40 (2014), 128–139.
105. Belcheva, A., Irrazabal, T., Robertson, S.J., et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158 (2014), 288–299.
106. Sengupta, S., Muir, J.G., Gibson, P.R., Does butyrate protect from colorectal cancer?. J Gastroenterol Hepatol 21 (2006), 209–218.
107. Freeman, H.J., Effects of differing concentrations of sodium butyrate on 1,2-dimethylhydrazine-induced rat intestinal neoplasia. Gastroenterology 91 (1986), 596–602.
108. Donohoe, D.R., Collins, L.B., Wali, A., et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 48 (2012), 612–626.
109. Dejea, C.M., Wick, E.C., Hechenbleikner, E.M., et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A 111 (2014), 18321–18326.
110. Purcell, R.V., Pearson, J., Aitchison, A., et al. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS One, 12, 2017, e0171602.
111. Wu, S., Rhee, K.J., Albesiano, E., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 (2009), 1016–1022.
112. Housseau, F., Wu, S., Wick, E.C., et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res 76 (2016), 2115–2124.
113. DeStefano Shields, C.E., Oncology, Do, Van Meerbeke, S.W., et al. Reduction of murine colon tumorigenesis driven by enterotoxigenic bacteroides fragilis using cefoxitin treatment. J Infect Dis 214 (2018), 122–129.
114. Arthur, J.C., Perez-Chanona, E., Muhlbauer, M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
115. Dejea, C.M., Fathi, P., Craig, J.M., et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359 (2018), 592–597.
116. Castellarin, M., Warren, R.L., Freeman, J.D., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22 (2012), 299–306.
117. Gao, Z., Guo, B., Gao, R., et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol, 6, 2015, 20.
118. Hibberd, A.A., Lyra, A., Ouwehand, A.C., et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol, 4, 2017, e000145.
119. Yu, T., Guo, F., Yu, Y., et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170 (2017), 548–563.e16.
120. Kostic, A.D., Chun, E., Robertson, L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2013), 207–215.
121. Bullman, S., Pedamallu, C.S., Sicinska, E., et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358:6369 (2017), 1443–1448.
122. Coley, W.B., II. Contribution to the knowledge of sarcoma. Ann Surg 14 (1891), 199–220.
123. Morales, A., Eidinger, D., Bruce, A.W., Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol 116 (1976), 180–183.
124. Kaiser, J., Couzin-Frankel, J., Cancer immunotherapy sweeps Nobel for medicine. Science, 362, 2018, 13.
125. Chapman, P.B., D'Angelo, S.P., Wolchok, J.D., Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 372 (2015), 2073–2074.
126. Weber, J.S., Current perspectives on immunotherapy. Semin Oncol 41:Suppl 5 (2014), S14–S29.
127. Viaud, S., Flament, C., Zoubir, M., et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 71 (2011), 661–665.
128. Liang, S.C., Tan, X.-Y., Luxenberg, D.P., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203 (2006), 2271–2279.
129. Iida, N., Dzutsev, A., Stewart, C.A., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342 (2013), 967–970.
130. Vetizou, M., Pitt, J.M., Daillere, R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084.
131. Sivan, A., Corrales, L., Hubert, N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350:6264 (2015), 1084–1089.
132. Matson, V., Fessler, J., Bao, R., et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science 359 (2018), 104–108.
133. Pushalkar, S., Hundeyin, M., Daley, D., et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 8 (2018), 403–416.
134. Rahib, L., Smith, B.D., Aizenberg, R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
135. Rhim Andrew, D., Mirek Emily, T., Aiello Nicole, M., et al. EMT and dissemination precede pancreatic tumor formation. Cell 148 (2012), 349–361.
136. Tiegs, G., Lohse, A.W., Immune tolerance: what is unique about the liver. J Autoimmun 34 (2010), 1–6.
137. Le, D.T., Lutz, E., Uram, J.N., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36 (2013), 382–389.
138. Royal, R.E., Levy, C., Turner, K., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33 (2010), 828–833.
139. Le, D.T., Durham, J.N., Smith, K.N., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
140. Zambirinis, C.P., Pushalkar, S., Saxena, D., et al. Pancreatic cancer, inflammation, and microbiome. Cancer J 20 (2014), 195–202.
141. Guerra, C., Schuhmacher, A.J., Canamero, M., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 (2007), 291–302.
142. Daniluk, J., Liu, Y., Deng, D., et al. An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122 (2012), 1519–1528.
143. Chang, H.-H., Moro, A., Takakura, K., et al. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PLoS One, 12, 2017, e0184455.
144. Ling, J., Kang, Ya, Zhao, R., et al. Kras G12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21 (2012), 105–120.
145. Lesina, M., Kurkowski, M.U., Ludes, K., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19 (2011), 456–469.
146. Daley, D., Zambirinis, C.P., Seifert, L., et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation. Cell 166 (2016), 1485–1499.e15.
147. Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 (2012), 836–847.
148. McAllister, F., Bailey, J.M., Alsina, J., et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25 (2014), 621–637.
149. Ochi, A., Nguyen, A.H., Bedrosian, A.S., et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209 (2012), 1671–1687.
150. Mirlekar, B., Michaud, D., Searcy, R., et al. IL35 hinders endogenous antitumor T-cell immunity and responsiveness to immunotherapy in pancreatic cancer. Cancer Immunol Res 6 (2018), 1014–1024.
151. Erez, N., Truitt, M., Olson, P., et al. Cancer-Associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 17 (2010), 135–147.
152. De Monte, L., Reni, M., Tassi, E., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208 (2011), 469–478.
153. Garg, B., Giri, B., Modi, S., et al. NFκB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via upregulation of CXCL12. Gastroenterology 155 (2018), 880–891.e8.
154. Feig, C., Jones, J.O., Kraman, M., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110 (2013), 20212–20217.
155. Winograd, R., Byrne, K.T., Evans, R.A., et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 3 (2015), 399–411.
156. Sharif, R., Dawra, R., Wasiluk, K., et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut 58 (2009), 813–819.
157. Tsuji, Y., Watanabe, T., Kudo, M., et al. Sensing of commensal organisms by the intracellular sensor NOD1 mediates experimental pancreatitis. Immunity 37 (2012), 326–338.
158. Hoque, R., Sohail, M., Malik, A., et al. TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology 141 (2011), 358–369.
159. Ochi, A., Graffeo, C.S., Zambirinis, C.P., et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 122 (2012), 4118–4129.
160. Daley, D., Mani, V.R., Mohan, N., et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med 23 (2017), 556–567.
161. Daley, D., Mani, V.R., Mohan, N., et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 214 (2017), 1711–1724.
162. Zambirinis, C.P., Levie, E., Nguy, S., et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med 212 (2015), 2077–2094.
163. Arora N, Majumder K, Modi S, et al. Analysis of gut microbiome in KPC pancreatic tumor mice. Meeting of the American Pancreatic Association, 2014.
164. Sethi, V., Kurtom, S., Tarique, M., et al. Depletion of the gut microbiota decreases pancreatic cancer burden by modulating the immune system. Pancreatology 18 (2018), S90–S91.
165. Sethi, V., Kurtom, S., Tarique, M., et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155 (2018), 33–37.e6.
166. Yoshimoto, S., Loo, T.M., Atarashi, K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
167. Ma, C., Han, M., Heinrich, B., et al. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 360(6391), 2018.
168. Geller, L.T., Barzily-Rokni, M., Danino, T., et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357 (2017), 1156–1160.
169. Olarerin-George, A.O., Hogenesch, J.B., Assessing the prevalence of mycoplasma contamination in cell culture via a survey of NCBI's RNA-seq archive. Nucleic Acids Res 43 (2015), 2535–2542.
170. Trikudanathan, G., Philip, A., Dasanu, C.A., et al. Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 12 (2011), 26–31.
171. Xiao, M., Wang, Y., Gao, Y., Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS One, 8, 2013, e75559.
172. Michaud, D.S., Izard, J., Wilhelm-Benartzi, C.S., et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62 (2013), 1764–1770.
173. Fan, X., Alekseyenko, A.V., Wu, J., et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67 (2018), 120–127.
174. Michaud, D.S., Joshipura, K., Giovannucci, E., et al. A Prospective study of periodontal disease and pancreatic cancer in US male health professionals. JNCI 99 (2007), 171–175.
175. Swidsinski, A., Schlien, P., Pernthaler, A., et al. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 54 (2005), 388–395.
176. Nistal, E., Caminero, A., Herrán, A.R., et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 18 (2012), 649–656.
177. Bischoff, S.C., Barbara, G., Buurman, W., et al. Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol, 14, 2014, 189.
178. Lowenfels, A.B., Maisonneuve, P., Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006), 197–209.
179. Nowotschin, S., Hadjantonakis, A.-K., Use of KikGR a photoconvertible green-to-red fluorescent protein for cell labeling and lineage analysis in ES cells and mouse embryos. BMC Dev Biol, 9, 2009, 49.
180. Benakis, C., Brea, D., Caballero, S., et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδT cells. Nat Med 22 (2016), 516–523.
181. Theys, J., Barbe, S., Landuyt, W., et al. Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther 3 (2003), 207–221.
182. Xu, Z., Vonlaufen, A., Phillips, P.A., et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 177 (2010), 2585–2596.
183. Apte, M.V., Wilson, J.S., Lugea, A., et al. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144 (2013), 1210–1219.
184. Costa-Silva, B., Aiello, N.M., Ocean, A.J., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17 (2015), 816–826.
185. Hoffmann, C., Dollive, S., Grunberg, S., et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One, 8, 2013, e66019.
186. Cadwell, K., The virome in host health and disease. Immunity 42 (2015), 805–813.
187. Singh, V., Yeoh, B.S., Chassaing, B., et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175 (2018), 679–694.e22.
188. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444, 2006, 1027.
189. Ridaura, V.K., Faith, J.J., Rey, F.E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013, 1241214.
190. Tan, C., Ling, Z., Huang, Y., et al. Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas 44 (2015), 868–875.
191. Schulz, M.D., Atay, Ç., Heringer, J., et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature, 514, 2014, 508.
192. Wong, C.H., Siah, K.W., Lo, A.W., Estimation of clinical trial success rates and related parameters. Biostatistics 20 (2019), 273–286.
193. Sacksteder, M.R., Occurrence of spontaneous tumors in the germfree F344 rat. J Natl Cancer Inst 57 (1976), 1371–1373.
194. Reddy, B.S., Watanabe, K., Effect of intestinal microflora on 3,2′-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. JNCI 61 (1978), 1269–1271.
195. Laqueur, G.L., Matsumoto, H., Yamamoto, R.S., Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J Natl Cancer Inst 67 (1981), 1053–1055.
196. Watanabe, T., Tada, M., Nagai, H., et al. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 115 (1998), 642–648.
197. Wang, T.C., Dangler, C.A., Chen, D., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118 (2000), 36–47.
198. Fox, J.G., Rogers, A.B., Ihrig, M., et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 63 (2003), 942–950.
199. Kado, S., Uchida, K., Funabashi, H., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor β chain and p53 double-knockout mice. Cancer Res 61 (2001), 2395–2398.
200. Newman, J.V., Kosaka, T., Sheppard, B.J., et al. Bacterial infection promotes colon tumorigenesis in Apc Min/+ mice. J Infect Dis 184 (2001), 227–230.
201. Vannucci, L., Stepankova, R., Kozakova, H., et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol 32 (2008), 609–617.
202. Grivennikov, S.I., Wang, K., Mucida, D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491 (2012), 254–258.
203. Li, Y., Kundu, P., Seow, S.W., et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APC Min/+ mice. Carcinogenesis 33 (2012), 1231–1238.
204. Couturier-Maillard, A., Secher, T., Rehman, A., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 123 (2013), 700–711.
205. Hoste, E., Arwert, E.N., Lal, R., et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun, 6, 2015, 5932.
206. Thomas, R.M., Gharaibeh, R.Z., Gauthier, J., et al. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models. Carcinogenesis 39 (2018), 1068–1078.
207. Rao, V.P., Poutahidis, T., Ge, Z., et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 66 (2006), 7395–7400.
208. Fox, J.G., Feng, Y., Theve, E.J., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59 (2010), 88–97.
209. Le Noci, V., Guglielmetti, S., Arioli, S., et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. Cell Rep 24 (2018), 3528–3538.
210. Nomura, A., Stemmermann, G.N., Chyou, P.-H., et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325 (1991), 1132–1136.
211. Wong, B., Lam, S., Wong, W., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004), 187–194.
212. Roggero, E., Zucca, E., Pinotti, G., et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122 (1995), 767–769.
213. Ferreri, A.J., Govi, S., Pasini, E., et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 30 (2012), 2988–2994.
214. Paulos, C.M., Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8(+) T cells via TLR4 signaling. J Clin Invest 117 (2007), 2197–2204.
215. Chen, X.Z., Wang, R., Chen, H.N., et al. Cytotoxin-associated gene A-negative strains of Helicobacter pylori as a potential risk factor of pancreatic cancer: a meta-analysis based on nested case-control studies. Pancreas 44 (2015), 1340–1344.
216. Farrell, J.J., Zhang, L., Zhou, H., et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61 (2012), 582–588.
217. Mitsuhashi, K., Nosho, K., Sukawa, Y., et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6 (2015), 7209–7220.